Beta₂-microglobulin amyloidosis in renal failure:
Understanding this recently recognized condition

J. Kay

Abstract

Beta₂-microglobulin amyloidosis can cause significant suffering in patients with chronic renal failure. Although renal transplantation is currently the only treatment, medical and surgical therapies may decrease pain and disability.

Author

Jonathan Kay, MD
Section of Rheumatology, Lahey Clinic; assistant clinical professor of medicine, Harvard Medical School

John D. Clough, M.D., editor-in-chief
Linda K. Hengstler, editor and publisher
Phillip E. Canuto, executive editor
Ray Borazanian, managing editor

The Cleveland Clinic Foundation
Cleveland Clinic Journal of Medicine, NA32
9500 Euclid Avenue
Cleveland, Ohio 44195

216.444.2661, FAX 216.444.9385, ccjm@ccf.org

This page maintained by the Division of Education, education@ccf.org. 3/99